Principal Investigator
Carl Landgren
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230969
Clinical Trial Summary
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3
Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Myeloma
Contact Information
Phone Number
305-243-2647